The National Health Insurance Administration (NHIA) will evaluate including a one-time gene therapy to treat individuals with hemophilia B in the NHI drug reimbursement scheme after it is approved in Taiwan, an NHIA official said Monday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
-
Culture
-
Cross-Strait
Xi-Cheng meeting tied to efforts to block Taiwan arms bill: MAC
04/02/2026 09:26 PM -
Society
NT$2 plastic bag wins NT$10 million in Taiwan's invoice lottery
04/02/2026 08:59 PM -
Society
Groups decry delays in case over Indonesian fisher's death at sea
04/02/2026 08:24 PM -
Society
Taiwan reports first domestic H7 flu infection to WHO
04/02/2026 08:19 PM